Semenova V A, Schmidt D S, Taylor T H, Li H, Steward-Clark E, Soroka S D, Ballard M M, Quinn C P
Centers for Disease Control and Prevention, Atlanta, GA 30333, USA.
Vaccine. 2007 Feb 26;25(10):1780-8. doi: 10.1016/j.vaccine.2006.11.028. Epub 2006 Nov 27.
The anti-PA IgG1, IgG2, IgG3, and IgG4 subclass responses to clinical anthrax and to different numbers of anthrax vaccine adsorbed (AVA, BioThrax) injections were determined in a cross-sectional study of sera from 63 vaccinees and 13 clinical anthrax patients. The data show that both vaccination with three AVA injections and clinical anthrax elicit anti-PA IgG1, IgG2, and IgG3 subclass responses. An anti-PA IgG4 response was detected in AVA recipients after the fourth injection. The anthrax lethal toxin (LTx) neutralization efficacy of sera from recipients who received 4 to > or =10 AVA injections did not vary significantly in relation to changes in distribution of anti-PA IgG1 and IgG4 subclasses.
在一项针对63名疫苗接种者和13名临床炭疽患者血清的横断面研究中，测定了针对临床炭疽以及不同剂量吸附炭疽疫苗（AVA，BioThrax）注射的抗保护性抗原（PA）IgG1、IgG2、IgG3和IgG4亚类反应。数据表明，三次AVA注射疫苗接种和临床炭疽均能引发抗PA IgG1、IgG2和IgG3亚类反应。在接受第四次注射后，AVA接种者中检测到抗PA IgG4反应。接受4至≥10次AVA注射的接种者血清的炭疽致死毒素（LTx）中和效力，与抗PA IgG1和IgG4亚类分布的变化并无显著差异。
